CN108347929A - 用于治疗疱疹病毒诱导的病况的方法和组合物 - Google Patents

用于治疗疱疹病毒诱导的病况的方法和组合物 Download PDF

Info

Publication number
CN108347929A
CN108347929A CN201680046420.0A CN201680046420A CN108347929A CN 108347929 A CN108347929 A CN 108347929A CN 201680046420 A CN201680046420 A CN 201680046420A CN 108347929 A CN108347929 A CN 108347929A
Authority
CN
China
Prior art keywords
virus
day
less
administered
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680046420.0A
Other languages
English (en)
Chinese (zh)
Inventor
道格拉斯·V·法勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Priority to CN202310699709.4A priority Critical patent/CN116712552A/zh
Publication of CN108347929A publication Critical patent/CN108347929A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680046420.0A 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物 Pending CN108347929A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310699709.4A CN116712552A (zh) 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182071P 2015-06-19 2015-06-19
US62/182,071 2015-06-19
PCT/US2016/038148 WO2016205695A1 (en) 2015-06-19 2016-06-17 Methods and compositions for treating herpesvirus induced conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310699709.4A Division CN116712552A (zh) 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物

Publications (1)

Publication Number Publication Date
CN108347929A true CN108347929A (zh) 2018-07-31

Family

ID=57546411

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680046420.0A Pending CN108347929A (zh) 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物
CN202310699709.4A Pending CN116712552A (zh) 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310699709.4A Pending CN116712552A (zh) 2015-06-19 2016-06-17 用于治疗疱疹病毒诱导的病况的方法和组合物

Country Status (5)

Country Link
US (3) US20180185345A1 (enExample)
EP (1) EP3310168B1 (enExample)
JP (2) JP7366385B2 (enExample)
CN (2) CN108347929A (enExample)
WO (1) WO2016205695A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187751A (zh) * 2020-01-19 2020-05-22 中国农业科学院兰州兽医研究所 一种用于构建幼畜心肌炎细胞模型的细胞系及构建方法
CN112111006A (zh) * 2020-08-27 2020-12-22 北京三安新特生物科技有限公司 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒
US10953011B2 (en) 2019-05-31 2021-03-23 Viracta Therapeutics Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
CN112877275A (zh) * 2021-02-04 2021-06-01 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
CN112980878A (zh) * 2021-02-04 2021-06-18 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN114404438A (zh) * 2019-07-18 2022-04-29 北京市农林科学院 Trifluridine在抑制犬细小病毒中的应用
US12427152B2 (en) 2016-07-15 2025-09-30 Viracta Therapeutics, Inc. HDAC inhibitors for use with NK cell based therapies

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20230190756A1 (en) * 2017-12-08 2023-06-22 Boris Farber Pharmaceutical formulation for the elimination of causative agents of herpesviral infections from the tissues of a macroorganism
JP7194458B2 (ja) 2018-07-19 2022-12-22 国立大学法人大阪大学 ウイルス計測方法、ウイルス計測装置、およびストレス判定装置
AR119033A1 (es) * 2019-05-31 2021-11-17 Viracta Therapeutics Inc Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
TW202110444A (zh) * 2019-08-28 2021-03-16 大陸商深圳微芯生物科技股份有限公司 一種西達本胺藥物組合物及其製備方法和用途
JP2022552642A (ja) * 2019-10-07 2022-12-19 ヴィラクタ サブシディアリー，インク． 副作用が軽減されたｈｄａｃ治療の調剤
EP4232076A1 (en) * 2020-10-20 2023-08-30 The Chancellor, Masters and Scholars of The University of Oxford Methods and compositions for treating epstein barr virus-associated cancer
WO2023190843A1 (ja) 2022-03-31 2023-10-05 住友重機械工業株式会社 支援装置、作業機械、プログラム
WO2023244968A1 (en) * 2022-06-13 2023-12-21 Viracta Subsidiary, Inc. Methods of treating autoimmune disorders with histone deacetylase inhibitors
EP4622714A1 (en) * 2022-11-21 2025-10-01 Henderson, Theodore Treatment using an antiviral compound and spironolactone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331313A1 (en) * 2010-03-11 2013-12-12 Trustees Of Boston University Methods and compositions for treating viral or virally-induced conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
WO2011038224A1 (en) * 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
EP2755648B1 (en) * 2011-09-13 2017-03-08 Pharmacyclics LLC Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9415070B2 (en) * 2012-11-09 2016-08-16 Massachusetts Institute Of Technology Methods and compositions for localized delivery of agents to virally infected cells and tissues
CN104083763A (zh) 2014-07-16 2014-10-08 中国人民解放军军事医学科学院野战输血研究所 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130331313A1 (en) * 2010-03-11 2013-12-12 Trustees Of Boston University Methods and compositions for treating viral or virally-induced conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAJAL K GHOSH ET AL: "Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents", 《BLOOD》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12427152B2 (en) 2016-07-15 2025-09-30 Viracta Therapeutics, Inc. HDAC inhibitors for use with NK cell based therapies
CN114206447A (zh) * 2019-05-31 2022-03-18 维拉克塔附属公司 用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法
US10953011B2 (en) 2019-05-31 2021-03-23 Viracta Therapeutics Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CN114404438B (zh) * 2019-07-18 2023-07-21 北京市农林科学院 Trifluridine在制备抑制犬细小病毒复制的药物中的用途
CN114404438A (zh) * 2019-07-18 2022-04-29 北京市农林科学院 Trifluridine在抑制犬细小病毒中的应用
CN112569243A (zh) * 2019-09-30 2021-03-30 神农医药科技有限公司 制备治疗阿尔茨海默病的药物
CN111187751A (zh) * 2020-01-19 2020-05-22 中国农业科学院兰州兽医研究所 一种用于构建幼畜心肌炎细胞模型的细胞系及构建方法
CN112111006B (zh) * 2020-08-27 2022-06-07 北京弘进久安生物科技有限公司 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒
CN112111006A (zh) * 2020-08-27 2020-12-22 北京三安新特生物科技有限公司 抗牛结节性皮肤病病毒的抗体、检测试纸及试剂盒
CN112980878A (zh) * 2021-02-04 2021-06-18 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN112877275A (zh) * 2021-02-04 2021-06-01 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用
CN112980878B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac8基因敲除的bhk-21细胞系及其构建方法和应用
CN112877275B (zh) * 2021-02-04 2023-03-31 中国农业科学院兰州兽医研究所 Hdac2基因敲除的bhk-21细胞系及其构建方法和应用

Also Published As

Publication number Publication date
JP7366385B2 (ja) 2023-10-23
US20240041848A1 (en) 2024-02-08
EP3310168A1 (en) 2018-04-25
US20210046061A1 (en) 2021-02-18
JP2022058416A (ja) 2022-04-12
EP3310168B1 (en) 2024-08-21
CN116712552A (zh) 2023-09-08
EP3310168A4 (en) 2019-03-06
US20180185345A1 (en) 2018-07-05
HK1254168A1 (en) 2019-07-12
WO2016205695A1 (en) 2016-12-22
JP2018517757A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
US20240041848A1 (en) Methods and compositions for treating herpesvirus induced conditions
US12083119B2 (en) Methods and compositions for treating viral or virally-induced conditions
US20230346788A1 (en) Methods for treating viral disorders
US20240058347A1 (en) Dosages for hdac treatment with reduced side effects
US10953011B2 (en) Methods of treating virally associated cancers with histone deacetylase inhibitors
WO2020243326A1 (en) Methods of treating virally associated cancers with histone deacetylase inhibitors
HK1254168B (en) Combinations of a nucleoside analog and an inducing agent for use in treating herpesvirus-induced conditions
WO2023244968A1 (en) Methods of treating autoimmune disorders with histone deacetylase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180731